Stock Analysis
United Therapeutics CorpUTHR
P/E 17.44×· 5Y range 10.73–22.16×· 66th percentile of history
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy22 analystsP/E 17.4× sits at the 66th percentile of its 5.0513347022587265-year history.
Cash covers 7767% of debt · FY 2025.
PMP Verdict
High quality, fairly valued
Strengths
- Profitability95
- Growth75
Strong fundamentals at a reasonable valuation.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 20.9 — safe-zone balance sheet
- ✓ROE 20.5% — efficient capital deployment
- ✓Revenue CAGR 17.2% — durable top-line growth
- ✓Interest coverage 26.8× — debt well covered
What's happening with UTHR
Profile
Strong profitability, growth and financial health; valuation lags behind.
How is each axis scored?
- Valuation39/100 · Weak
- P/E vs own history (66th pct)5/25
- FCF yield (4.8%)12/25
- P/S (7.2x)12/25
- EV/EBIT (n/a)10/25
- Growth75/100 · Strong
- Revenue CAGR (17.2%)20/25
- Net income CAGR (29.4%)25/25
- EPS CAGR 5Y (29.0%)25/25
- Fwd implied growth (0.9%)5/25
- Profitability95/100 · Strong
- ROIC (29.6%)25/25
- ROE (20.5%)20/25
- Net margin (41.6%)25/25
- Operating margin (44.4%)25/25
- Financial Health75/100 · Strong
- Altman Z (20.92)25/25
- Current ratio (5.73)25/25
- Interest coverage (26.8x)25/25
- Net cash / debt (n/a)0/25
- Quality69/100 · Moderate
- Piotroski F (7/9)22/25
- Beneish M (-2.63)25/25
- FCF conversion (83%)22/25
- Margin stability (σ 44.4%)0/25
- Moat68/100 · Moderate
- ROIC >12% years (9/10 yrs)25/25
- Median gross margin (92.0%)25/25
- FCF-positive years (9/10 yrs)18/25
- Worst-year net margin (worst -7.2%)0/25
About United Therapeutics Corp
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. Show more
The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Headquarters: SILVER SPRING, MD · Employees: 1,400 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
39DP/E (TTM)17.4xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 10.7x–22.2x · 66th pct
P/FCF21.4xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield4.8%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 3.6%–8.4% · 14th pct
P/S (TTM)7.25xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 4.3x–9.0x · 84th pct
EV/EBITDA14.4xB
Grade B: FairEnterprise value / EBITDA (Finnhub) — capital-structure neutral — vs own 5Y history: 7.0x–20.1x · 84th pct
EV/Sales6.8xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E17.3xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio3.57xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio2.11C
Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
95A+ROIC29.6%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE20.5%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA18.0%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin41.6%A
Grade A: HighNet Income / Revenue
Operating Margin44.4%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin86.1%A
Grade A: PremiumGross Profit / Revenue
FCF Margin34.6%A
Grade A: HighFCF / Revenue
True FCF Margin29.7%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
75B+Revenue CAGR17.2%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR29.4%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)29.0%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth0.9%B
Grade B: LowAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-8.5%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income11.9%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue4.9%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score20.92A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio5.73xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio5.41xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage26.8xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
69BPiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.63A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion83.4%A
Grade A: StrongFCF / Net Income
Margin Stability44.4%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue18.8%D
Grade D: HeavyTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.43xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
ROTHBLATT MARTINE A Filed | ROTHBLATT MARTINE A | Option exercise | -9500 | |
ROTHBLATT MARTINE A Filed | ROTHBLATT MARTINE A | SellOpen market sale | -40 | |
ROTHBLATT MARTINE A Filed | ROTHBLATT MARTINE A | SellOpen market sale | -480 | |
ROTHBLATT MARTINE A Filed | ROTHBLATT MARTINE A | SellOpen market sale | -480 | |
ROTHBLATT MARTINE A Filed | ROTHBLATT MARTINE A | SellOpen market sale | -400 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
ROTHBLATT MARTINE A Filed | ROTHBLATT MARTINE A | SellOpen market sale | -883 | |
ROTHBLATT MARTINE A Filed | ROTHBLATT MARTINE A | SellOpen market sale | -1930 | |
ROTHBLATT MARTINE A Filed | ROTHBLATT MARTINE A | SellOpen market sale | -2002 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
68BROIC >12% Years9/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)92.0%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years9/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-7.2%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$30.56
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$62.38
Cash & short-term investments per share (Finnhub)
Book Value / Share$149.97
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$2.66B
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$6.40B
Shareholders' equity (book value)
Asset / Liability8.81xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$22.87B
Current Market Capitalization
Beta0.49B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: United Therapeutics Corp (UTHR)
UTHR is down 1.55% at the last close. United Therapeutics Corp meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 20.92 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.63 suggests a low likelihood of earnings manipulation.
- Revenue has compounded at roughly 17% annually, with net income growing about 29% per year — a strong growth profile.
- United Therapeutics Corp converts about 35% of revenue into free cash flow — strong cash generation.
- United Therapeutics Corp posted a net loss in 1 of 10 available completed fiscal years (2016–2025).
- Return on equity of 20.5% is well above the market average.
See how UTHR ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all UTHR moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 30 | Regular | 546.92 | +13.59% | 8.20 |
| Sep 30 | After-hours | 545.18 | +13.23% | 8.00 |
| Sep 24 | Regular | 470.89 | -3.79% | -2.41 |
| Sep 24 | After-hours | 472.21 | -3.52% | -2.22 |
Frequently Asked Questions about UTHR
What is the current United Therapeutics Corp (UTHR) stock price?
UTHR is trading at $533.12 at the last market close, down 1.55% on the session. PreMarketPrice tracks UTHR pre-market, intraday and after-hours prices.
Is UTHR stock a buy right now?
PreMarketPrice's quantitative model rates United Therapeutics Corp's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is UTHR stock overvalued?
United Therapeutics Corp trades at a trailing P/E of 17.4 and our valuation score rates it 39/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does United Therapeutics Corp report earnings?
No confirmed earnings date is currently scheduled for UTHR. The Earnings section lists recent reports and updates as dates are announced.
What sector does United Therapeutics Corp operate in?
United Therapeutics Corp operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does United Therapeutics Corp do?
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs.
About United Therapeutics Corp (UTHR) Stock
United Therapeutics Corp (UTHR) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, United Therapeutics Corp is trading at $533.12, down 1.55% on the day with a market capitalization of $22.9 billion. The financial health score for UTHR is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for UTHR stock.
UTHR Stock Analysis & Key Metrics
On PreMarketPrice, you can track United Therapeutics Corp (UTHR) across multiple dimensions:
- Pre-market price & movement: Real-time UTHR stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for UTHR with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for United Therapeutics Corp across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for UTHR.
- Sector peers: Compare UTHR against 6 other healthcare stocks on key financial metrics.
Is UTHR a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate United Therapeutics Corp (UTHR) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.United Therapeutics Corp (UTHR) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.